代谢相关脂肪性肝病与肌肉减少症的研究进展OA
Research Progress on Metabolic Fatty Liver Disease and Sarcopenia
代谢相关脂肪性肝病(metabolic associated fatty liver disease,MAFLD)流行率由于全球肥胖流行病的增加而在近年来显著增加.肌肉减少症(sarcopenia,SP)会通过减少运动能力和产生各种肌肉相关的化学因子来加重MAFLD.二者相互影响,加剧病情.因此,全面了解两者的相互影响及共存情况显得至关重要.本文对MAFLD和肌肉减少症之间的病理生物学联系、危害,肌肉减少症的临床评估与诊断建议等的最新研究进展进行了综述,并提出了基于证据的治疗策略,以改善患者生活质量,可供临床借鉴与参阅.
The prevalence of metabolic associated fatty liver disease(MAFLD)has increased substantially in recent years due to the global obesity epidemic.Sarcopenia(SP)exacerbates MAFLD through reduced physical capacity and altered myokine signaling.These two conditions interact synergistically,amplifying disease progression.A comprehensive understanding of the two diseases com-plex,particularly in the context of their coexistence,is therefore imperative.This comprehensive clinical update review examines the pathobiological interplay between MAFLD and sarcopenia,discusses their collective clinical impact,provides recommendations for the assessment and diagnosis of sarcopenia,and proposes evidence-based therapeutic strategies to improve patient quality of life.
ZHANG Lei;LIU Lidan;TANG Haoqing
Department of Internal Medicine,Luoyang New Milestone Hospital,Luoyang 471003,ChinaDepartment of Internal Medicine,The 96606th Troop Hospital of the People's Liberation Army,Luoyang 471003,ChinaDepartment of Internal Orthopedics,The Sixth People's Hospital of Luoyang,Luoyang 471003,China
医药卫生
代谢相关脂肪性肝病肌肉肌少症
Metabolic associated fatty liver diseaseSarcopenia
《西南医科大学学报》 2026 (1)
45-49,5
评论